적혈구증가증 시장 : 세계 산업 규모, 점유율, 동향, 기회, 예측 - 유형별, 치료법별, 투여 경로별, 유통 채널별, 지역별, 경쟁별(2020-2030년)

Polycythemia Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, Segmented By Type, By Treatment, By Route of Administration, By Distribution Channel, By Region and Competition, 2020-2030F

US $ 4,500 ￦ 6,292,000

Unprintable PDF (Single User License)

PDF 보고서를 1명만 이용할 수 있는 라이선스입니다. 인쇄 불가능하며, 텍스트의 Copy&Paste도 불가능합니다.

US $ 5,500 ￦ 7,691,000

PDF and Excel (Multi-User License)

PDF 및 Excel 보고서를 기업의 팀이나 기관에서 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 및 Excel 이용 범위와 동일합니다.

US $ 8,000 ￦ 11,187,000

PDF and Excel (Custom Research License)

PDF 및 Excel 보고서를 동일 기업의 모든 분이 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 및 Excel 이용 범위와 동일합니다. 80시간의 애널리스트 타임이 포함되어 있고 Copy & Paste 가능한 PPT 버전도 제공됩니다. 짧은 Bespoke 리서치 프로젝트 수행에 맞는 라이선스입니다.

한글목차

세계 적혈구증가증 시장은 2024년 18억 9,000만 달러로 평가되며 예측 기간 동안 CAGR 5.73%로 성장하여 2030년까지 26억 4,000만 달러에 달할 것으로 예상됩니다.

적혈구증가증은 적혈구 수가 과도하게 증가하여 혈전증, 뇌졸중, 심혈관질환과 같은 심각한 합병증을 유발할 수 있는 희귀한 혈액 질환입니다. 최근 몇 년 동안 진단 능력의 향상, 의료진과 환자들의 인식 제고, 고령화 및 생활습관 관련 혈액질환의 세계적 부담 증가 등으로 인해 시장은 눈에 띄게 성장하고 있습니다. 표적 치료를 포함한 첨단 치료법의 개발은 치료의 전망을 재구성하고 있습니다. 제약사들은 근본적인 유전자 변이를 해결하기 위한 연구를 활발히 진행하여 더 나은 결과와 삶의 질을 향상시킬 수 있는 정밀 의약품을 개발하고 있습니다. 바이오 제약회사와 학술 기관과의 협업은 적혈구증가증 관리의 혁신에 더욱 기여하고 있습니다.

시장 개요
예측 기간	2026-2030년
시장 규모 : 2024년	18억 9,000만 달러
시장 규모 : 2030년	26억 4,000만 달러
CAGR : 2025-2030년	5.73%
급성장 부문	원발성 적혈구증가증
최대 시장	북미

주요 시장 촉진요인

질병에 대한 인식 및 진단 향상

주요 시장 과제

제한된 질병 인식 및 진단

주요 시장 동향

표적 치료의 발전

목차

제1장 제품 개요

제2장 조사 방법

제3장 주요 요약

제4장 세계의 적혈구증가증 시장 전망

• 시장 규모 및 예측
  • 금액별
• 시장 점유율과 예측
  • 유형별(원발성 적혈구증가증, 이차성 적혈구증가증, 위성 적혈구증가증)
  • 치료법별(사혈, 아스피린, 골수 억제제, 선택적 세로토닌 재흡수 억제제, 기타)
  • 투여 경로별(경구, 정맥내, 근육내)
  • 유통 채널별(병원 약국, 소매 약국, 온라인 약국)
  • 지역별
  • 기업별(2024년)
• 시장 맵
  • 유형별
  • 치료법별
  • 투여 경로별
  • 유통 채널별
  • 지역별

제5장 아시아태평양의 적혈구증가증 시장 전망

• 시장 규모 및 예측
  • 금액별
• 시장 점유율과 예측
  • 유형별
  • 치료별
  • 투여 경로별
  • 유통 채널별
  • 국가별
• 아시아태평양 : 국가별 분석
  • 중국
  • 인도
  • 호주
  • 일본
  • 한국

제6장 유럽의 적혈구증가증 시장 전망

• 시장 규모 및 예측
• 시장 점유율과 예측
• 유럽 : 국가별 분석
  • 프랑스
  • 독일
  • 스페인
  • 이탈리아
  • 영국

제7장 북미의 적혈구증가증 시장 전망

• 시장 규모 및 예측
• 시장 점유율과 예측
  • 유형
• 북미 : 국가별 분석
  • 미국
  • 멕시코
  • 캐나다

제8장 남미의 적혈구증가증 시장 전망

• 시장 규모 및 예측
• 시장 점유율과 예측
• 남미 : 국가별 분석
  • 브라질
  • 아르헨티나
  • 콜롬비아

제9장 중동 및 아프리카의 적혈구증가증 시장 전망

• 시장 규모 및 예측
• 시장 점유율과 예측
• 중동 및 아프리카 : 국가별 분석
  • 남아프리카공화국
  • 사우디아라비아
  • 아랍에미리트

제10장 시장 역학

• 성장 촉진요인
• 과제

제11장 시장 동향과 발전

• 최근 동향
• 제품 출시
• 인수합병

제12장 세계의 적혈구증가증 시장 : SWOT 분석

제13장 Porter's Five Forces 분석

• 업계내 경쟁
• 신규 참여의 가능성
• 공급업체의 능력
• 고객의 능력
• 대체품의 위협

제14장 경쟁 구도

• Novartis AG
• Incyte Corporation
• Bristol-Myers Squibb Company
• Eli Lilly and Company
• PharmaEssentia Corporation
• Dr. Reddy's Laboratories Ltd.
• LC Laboratories
• Par Pharmaceutical
• TAJ LIFE SCIENCES PVT. LTD
• GSK plc

제15장 전략적 제안

제16장 조사 회사 소개 및 면책사항

ksm

영문 목차

영문목차

The Global Polycythemia Market was valued at USD 1.89 billion in 2024 and is projected to reach USD 2.64 billion by 2030, growing at a CAGR of 5.73% during the forecast period. Polycythemia is a rare hematologic disorder marked by an excessive increase in red blood cell count, which can lead to serious complications such as thrombosis, stroke, or cardiovascular events. The market has witnessed notable expansion in recent years, driven by enhanced diagnostic capabilities, rising awareness among healthcare providers and patients, and the increasing global burden of hematologic conditions linked to aging populations and lifestyle factors. The development of advanced treatment options, including targeted therapies, is reshaping the therapeutic landscape. Pharmaceutical companies are actively pursuing research to address underlying genetic mutations and develop precision medicines that offer better outcomes and improved quality of life. Collaborations between biopharma firms and academic institutions are further contributing to innovations in polycythemia management.

Market Overview
Forecast Period	2026-2030
Market Size 2024	USD 1.89 Billion
Market Size 2030	USD 2.64 Billion
CAGR 2025-2030	5.73%
Fastest Growing Segment	Primary Polycythemia
Largest Market	North America

Key Market Drivers

Increasing Disease Awareness and Diagnosis

Improved awareness and diagnostic capabilities are key drivers propelling the global polycythemia market. Historically underdiagnosed due to non-specific symptoms, polycythemia is now more frequently detected owing to growing clinical vigilance and the availability of routine hematological testing. Healthcare professionals are becoming increasingly adept at identifying early signs such as elevated hematocrit levels and persistent fatigue, leading to earlier interventions and improved prognosis. Public health campaigns, scientific publications, and advocacy by patient organizations have also played a vital role in highlighting the disease. With improved access to diagnostic tools like complete blood count (CBC) and genetic screening, more cases are now being recognized and treated promptly. As reported in a 2020 MDPI study, global annual incidence rates highlight a higher prevalence of polycythemia vera (PV) and essential thrombocythemia (ET), underscoring the need for early diagnosis and targeted care.

Key Market Challenges

Limited Disease Awareness and Diagnosis

Despite progress, limited disease recognition remains a significant barrier to market growth. Due to its rarity and overlapping symptoms with other conditions, polycythemia often goes undetected or misdiagnosed. Many healthcare professionals, particularly in primary care settings, may lack familiarity with the disease's clinical presentation or its diagnostic criteria. As a result, patients can experience delays in receiving appropriate care, which increases their risk of developing severe complications. The general population also remains largely unaware of polycythemia, leading to a low rate of self-referral or health-seeking behavior for symptoms such as headaches or unexplained fatigue. Addressing this gap requires coordinated efforts from medical societies, pharmaceutical companies, and advocacy groups to enhance education and screening practices. Expanding outreach and training programs is essential to improving early detection and patient outcomes.

Key Market Trends

Advancements in Targeted Therapies

Targeted therapy development is a key trend reshaping the global polycythemia market. Traditional treatments like therapeutic phlebotomy, while effective at symptom management, do not address the molecular basis of the disease. Innovations in drug development now focus on agents that inhibit specific pathways and genetic mutations, such as JAK2 V617F, which are commonly implicated in polycythemia vera. These therapies offer the promise of durable disease control with fewer side effects and a reduced need for invasive procedures. Pharmaceutical companies are investing heavily in R&D to bring to market precision medicines that not only manage symptoms but modify disease progression. This trend aligns with the broader movement toward personalized healthcare, offering tailored interventions based on a patient's unique genetic and molecular profile. The emergence of these therapies marks a critical step forward in improving long-term outcomes and elevating the standard of care for polycythemia patients.

Key Market Players

• Novartis AG
• Incyte Corporation
• Bristol-Myers Squibb Company
• Eli Lilly and Company
• PharmaEssentia Corporation
• Dr. Reddy's Laboratories Ltd.
• LC Laboratories
• Par Pharmaceutical
• Taj Life Sciences Pvt. Ltd
• GSK plc

Report Scope:

In this report, the Global Polycythemia Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Polycythemia Market, By Type:

• Primary Polycythemia
• Secondary Polycythemia
• Pseudopolycythemia

Polycythemia Market, By Treatment:

• Phlebotomy
• Aspirin
• Myelosuppressive Agents
• Selective Serotonin Reuptake Inhibitor
• Others

Polycythemia Market, By Route of Administration:

• Oral
• Intravenous
• Intramuscular

Polycythemia Market, By Distribution Channel:

• Hospital Pharmacies
• Retail Pharmacies
• Online Pharmacies

Polycythemia Market, By Region:

• North America
  • United States
  • Canada
  • Mexico
• Europe
  • France
  • United Kingdom
  • Italy
  • Germany
  • Spain
• Asia-Pacific
  • China
  • India
  • Japan
  • Australia
  • South Korea
• South America
  • Brazil
  • Argentina
  • Colombia
• Middle East & Africa
  • South Africa
  • Saudi Arabia
  • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Polycythemia Market.

Available Customizations:

Global Polycythemia Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

• Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

• 1.1. Market Definition
• 1.2. Scope of the Market
  • 1.2.1. Markets Covered
  • 1.2.2. Years Considered for Study
  • 1.2.3. Key Market Segmentations

2. Research Methodology

• 2.1. Objective of the Study
• 2.2. Baseline Methodology
• 2.3. Key Industry Partners
• 2.4. Major Association and Secondary Sources
• 2.5. Forecasting Methodology
• 2.6. Data Triangulation & Validation
• 2.7. Assumptions and Limitations

3. Executive Summary

• 3.1. Overview of the Market
• 3.2. Overview of Key Market Segmentations
• 3.3. Overview of Key Market Players
• 3.4. Overview of Key Regions/Countries
• 3.5. Overview of Market Drivers, Challenges, Trends

4. Global Polycythemia Market Outlook

• 4.1. Market Size & Forecast
  • 4.1.1. By Value
• 4.2. Market Share & Forecast
  • 4.2.1. By Type (Primary polycythemia, Secondary polycythemia, Pseudopolycythemia )
  • 4.2.2. By Treatment (Phlebotomy, Aspirin, Myelosuppressive Agents, Selective Serotonin Reuptake Inhibitor, Others)
  • 4.2.3. By Route of Administration (Oral, Intravenous, Intramuscular)
  • 4.2.4. By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies)
  • 4.2.5. By Region
  • 4.2.6. By Company (2024)
• 4.3. Market Map
  • 4.3.1. By Type
  • 4.3.2. By Treatment
  • 4.3.3. By Route of Administration
  • 4.3.4. By Distribution Channel
  • 4.3.5. By Region

5. Asia Pacific Polycythemia Market Outlook

• 5.1. Market Size & Forecast
  • 5.1.1. By Value
• 5.2. Market Share & Forecast
  • 5.2.1. By Type
  • 5.2.2. By Treatment
  • 5.2.3. By Route of Administration
  • 5.2.4. By Distribution Channel
  • 5.2.5. By Country
• 5.3. Asia Pacific: Country Analysis
  • 5.3.1. China Polycythemia Market Outlook
    • 5.3.1.1. Market Size & Forecast
      • 5.3.1.1.1. By Value
    • 5.3.1.2. Market Share & Forecast
      • 5.3.1.2.1. By Type
      • 5.3.1.2.2. By Treatment
      • 5.3.1.2.3. By Route of Administration
      • 5.3.1.2.4. By Distribution Channel
  • 5.3.2. India Polycythemia Market Outlook
    • 5.3.2.1. Market Size & Forecast
      • 5.3.2.1.1. By Value
    • 5.3.2.2. Market Share & Forecast
      • 5.3.2.2.1. By Type
      • 5.3.2.2.2. By Treatment
      • 5.3.2.2.3. By Route of Administration
      • 5.3.2.2.4. By Distribution Channel
  • 5.3.3. Australia Polycythemia Market Outlook
    • 5.3.3.1. Market Size & Forecast
      • 5.3.3.1.1. By Value
    • 5.3.3.2. Market Share & Forecast
      • 5.3.3.2.1. By Type
      • 5.3.3.2.2. By Treatment
      • 5.3.3.2.3. By Route of Administration
      • 5.3.3.2.4. By Distribution Channel
  • 5.3.4. Japan Polycythemia Market Outlook
    • 5.3.4.1. Market Size & Forecast
      • 5.3.4.1.1. By Value
    • 5.3.4.2. Market Share & Forecast
      • 5.3.4.2.1. By Type
      • 5.3.4.2.2. By Treatment
      • 5.3.4.2.3. By Route of Administration
      • 5.3.4.2.4. By Distribution Channel
  • 5.3.5. South Korea Polycythemia Market Outlook
    • 5.3.5.1. Market Size & Forecast
      • 5.3.5.1.1. By Value
    • 5.3.5.2. Market Share & Forecast
      • 5.3.5.2.1. By Type
      • 5.3.5.2.2. By Treatment
      • 5.3.5.2.3. By Route of Administration
      • 5.3.5.2.4. By Distribution Channel

6. Europe Polycythemia Market Outlook

• 6.1. Market Size & Forecast
  • 6.1.1. By Value
• 6.2. Market Share & Forecast
  • 6.2.1. By Type
  • 6.2.2. By Treatment
  • 6.2.3. By Route of Administration
  • 6.2.4. By Distribution Channel
  • 6.2.5. By Country
• 6.3. Europe: Country Analysis
  • 6.3.1. France Polycythemia Market Outlook
    • 6.3.1.1. Market Size & Forecast
      • 6.3.1.1.1. By Value
    • 6.3.1.2. Market Share & Forecast
      • 6.3.1.2.1. By Type
      • 6.3.1.2.2. By Treatment
      • 6.3.1.2.3. By Route of Administration
      • 6.3.1.2.4. By Distribution Channel
  • 6.3.2. Germany Polycythemia Market Outlook
    • 6.3.2.1. Market Size & Forecast
      • 6.3.2.1.1. By Value
    • 6.3.2.2. Market Share & Forecast
      • 6.3.2.2.1. By Type
      • 6.3.2.2.2. By Treatment
      • 6.3.2.2.3. By Route of Administration
      • 6.3.2.2.4. By Distribution Channel
  • 6.3.3. Spain Polycythemia Market Outlook
    • 6.3.3.1. Market Size & Forecast
      • 6.3.3.1.1. By Value
    • 6.3.3.2. Market Share & Forecast
      • 6.3.3.2.1. By Type
      • 6.3.3.2.2. By Treatment
      • 6.3.3.2.3. By Route of Administration
      • 6.3.3.2.4. By Distribution Channel
  • 6.3.4. Italy Polycythemia Market Outlook
    • 6.3.4.1. Market Size & Forecast
      • 6.3.4.1.1. By Value
    • 6.3.4.2. Market Share & Forecast
      • 6.3.4.2.1. By Type
      • 6.3.4.2.2. By Treatment
      • 6.3.4.2.3. By Route of Administration
      • 6.3.4.2.4. By Distribution Channel
  • 6.3.5. United Kingdom Polycythemia Market Outlook
    • 6.3.5.1. Market Size & Forecast
      • 6.3.5.1.1. By Value
    • 6.3.5.2. Market Share & Forecast
      • 6.3.5.2.1. By Type
      • 6.3.5.2.2. By Treatment
      • 6.3.5.2.3. By Route of Administration
      • 6.3.5.2.4. By Distribution Channel

7. North America Polycythemia Market Outlook

• 7.1. Market Size & Forecast
  • 7.1.1. By Value
• 7.2. Market Share & Forecast
  • 7.2.1. By Treatment
  • 7.2.2. Type
  • 7.2.3. By Distribution Channel
  • 7.2.4. By Route of Administration
  • 7.2.5. By Country
• 7.3. North America: Country Analysis
  • 7.3.1. United States Polycythemia Market Outlook
    • 7.3.1.1. Market Size & Forecast
      • 7.3.1.1.1. By Value
    • 7.3.1.2. Market Share & Forecast
      • 7.3.1.2.1. By Type
      • 7.3.1.2.2. By Treatment
      • 7.3.1.2.3. By Route of Administration
      • 7.3.1.2.4. By Distribution Channel
  • 7.3.2. Mexico Polycythemia Market Outlook
    • 7.3.2.1. Market Size & Forecast
      • 7.3.2.1.1. By Value
    • 7.3.2.2. Market Share & Forecast
      • 7.3.2.2.1. By Type
      • 7.3.2.2.2. By Treatment
      • 7.3.2.2.3. By Route of Administration
      • 7.3.2.2.4. By Distribution Channel
  • 7.3.3. Canada Polycythemia Market Outlook
    • 7.3.3.1. Market Size & Forecast
      • 7.3.3.1.1. By Value
    • 7.3.3.2. Market Share & Forecast
      • 7.3.3.2.1. By Type
      • 7.3.3.2.2. By Treatment
      • 7.3.3.2.3. By Route of Administration
      • 7.3.3.2.4. By Distribution Channel

8. South America Polycythemia Market Outlook

• 8.1. Market Size & Forecast
  • 8.1.1. By Value
• 8.2. Market Share & Forecast
  • 8.2.1. By Type
  • 8.2.2. By Treatment
  • 8.2.3. By Distribution Channel
  • 8.2.4. By Country
• 8.3. South America: Country Analysis
  • 8.3.1. Brazil Polycythemia Market Outlook
    • 8.3.1.1. Market Size & Forecast
      • 8.3.1.1.1. By Value
    • 8.3.1.2. Market Share & Forecast
      • 8.3.1.2.1. By Type
      • 8.3.1.2.2. By Treatment
      • 8.3.1.2.3. By Route of Administration
      • 8.3.1.2.4. By Distribution Channel
  • 8.3.2. Argentina Polycythemia Market Outlook
    • 8.3.2.1. Market Size & Forecast
      • 8.3.2.1.1. By Value
    • 8.3.2.2. Market Share & Forecast
      • 8.3.2.2.1. By Type
      • 8.3.2.2.2. By Treatment
      • 8.3.2.2.3. By Route of Administration
      • 8.3.2.2.4. By Distribution Channel
  • 8.3.3. Colombia Polycythemia Market Outlook
    • 8.3.3.1. Market Size & Forecast
      • 8.3.3.1.1. By Value
    • 8.3.3.2. Market Share & Forecast
      • 8.3.3.2.1. By Type
      • 8.3.3.2.2. By Treatment
      • 8.3.3.2.3. By Route of Administration
      • 8.3.3.2.4. By Distribution Channel

9. Middle East and Africa Polycythemia Market Outlook

• 9.1. Market Size & Forecast
  • 9.1.1. By Value
• 9.2. Market Share & Forecast
  • 9.2.1. By Type
  • 9.2.2. By Drug Type
  • 9.2.3. By Route of Administration
  • 9.2.4. By Distribution Channel
  • 9.2.5. By Country
• 9.3. MEA: Country Analysis
  • 9.3.1. South Africa Polycythemia Market Outlook
    • 9.3.1.1. Market Size & Forecast
      • 9.3.1.1.1. By Value
    • 9.3.1.2. Market Share & Forecast
      • 9.3.1.2.1. By Type
      • 9.3.1.2.2. By Treatment
      • 9.3.1.2.3. By Route of Administration
      • 9.3.1.2.4. By Distribution Channel
  • 9.3.2. Saudi Arabia Polycythemia Market Outlook
    • 9.3.2.1. Market Size & Forecast
      • 9.3.2.1.1. By Value
    • 9.3.2.2. Market Share & Forecast
      • 9.3.2.2.1. By Type
      • 9.3.2.2.2. By Drug Type
      • 9.3.2.2.3. By Route of Administration
      • 9.3.2.2.4. By Distribution Channel
  • 9.3.3. UAE Polycythemia Market Outlook
    • 9.3.3.1. Market Size & Forecast
      • 9.3.3.1.1. By Value
    • 9.3.3.2. Market Share & Forecast
      • 9.3.3.2.1. By Type
      • 9.3.3.2.2. By Treatment
      • 9.3.3.2.3. By Route of Administration
      • 9.3.3.2.4. By Distribution Channel

10. Market Dynamics

• 10.1. Drivers
• 10.2. Challenges

11. Market Trends & Developments

• 11.1. Recent Developments
• 11.2. Product Launches
• 11.3. Mergers & Acquisitions

12. Global Polycythemia Market: SWOT Analysis

13. Porter's Five Forces Analysis

• 13.1. Competition in the Industry
• 13.2. Potential of New Entrants
• 13.3. Power of Suppliers
• 13.4. Power of Customers
• 13.5. Threat of Substitute Product

14. Competitive Landscape

• 14.1. Novartis AG
  • 14.1.1. Business Overview
  • 14.1.2. Company Snapshot
  • 14.1.3. Products & Services
  • 14.1.4. Financials (In case of listed)
  • 14.1.5. Recent Developments
  • 14.1.6. Key Personnel Details
  • 14.1.7. SWOT Analysis
• 14.2. Incyte Corporation
• 14.3. Bristol-Myers Squibb Company
• 14.4. Eli Lilly and Company
• 14.5. PharmaEssentia Corporation
• 14.6. Dr. Reddy's Laboratories Ltd.
• 14.7. LC Laboratories
• 14.8. Par Pharmaceutical
• 14.9. TAJ LIFE SCIENCES PVT. LTD
• 14.10. GSK plc

15. Strategic Recommendations

16. About Us & Disclaimer

관련자료